



Diagnosing and Monitoring Suspected Cases of Canine Hypercortisolism and Hypoadrenocorticism.

Clinical Reference Guide

Hypercortisolism (Cushing's syndrome)

What is it?

Hypercortisolism (previously called hyperadrenocorticism) is an increase in glucocorticoid activity due to elevated cortisol concentrations.

Cushing's syndrome refers to the spectrum of clinical syndromes resulting from prolonged exposure to elevated glucocorticoid concentrations, whether originating from within the body (endogenous) or from external sources (exogenous).^{1,2}

Pathophysiology

ACTH-dependent hypercortisolism

Pituitary-dependent hypercortisolism (PDH)²

- + Most common form of hypercortisolism: 80-85% of dogs with hypercortisolism have this form.²
- + An autonomous adrenocorticotropic hormone (ACTH)-secreting pituitary tumour leads to increased release of ACTH, which then leads to bilateral adrenal hypertrophy and excess release of cortisol.
- + Most of these are adenomas, but invasive adenomas and carcinomas have also been reported.2

ACTH-independent hypercortisolism

Autonomous cortisol-secreting adrenal tumour²

- + 15-20% of Cushing's patients have this form.2
- + Adrenal tumour synthesises and secretes excess cortisol.
 - + Cortisol feeds back negatively to the hypothalamus and pituitary gland, leading to decreased release of corticotropin-releasing hormone (CRH) and ACTH.
 - + Decreased production of CRH/ACTH leads to atrophy of the contralateral adrenal gland.
- + Adenoma or carcinoma carcinoma in 63-75% of cases.²
- + Usually solitary and unilateral bilateral cases have been reported.2

Subdiagnostic Cushing's syndrome

A clinical syndrome in which a patient presents with clinical signs suggestive of Cushing's syndrome, yet dynamic testing results are normal.¹





latrogenic Cushing's syndrome

Results from prolonged administration of exogenous glucocorticoids – systemic or topical – leading to clinical signs of hypercortisolism.¹

Note: There are other uncommon forms of ACTH-dependent and ACTH-independent hypercortisolism which are beyond the scope of this document.

Clinical signs

Common	Less common	Uncommon
+ Polyuria/polydipsia	+ Lethargy	+ Ligament rupture
+ Polyphagia	+ Hyperpigmentation	+ Facial nerve palsy
+ Panting	+ Comedones	+ Pseudomyotonia
+ Abdominal distention	+ Thin skin	+ Testicular atrophy
+ Endocrine alopecia	+ Poor hair regrowth	+ Persistent anoestrus
+ Hepatomegaly	+ Urine leakage	
+ Muscle weakness		

Clinicopathologic findings

Haematology	Chemistry	Urinalysis
+ Stress leucogram (most consistent finding: lymphopaenia) + Thrombocytosis + Erythrocytosis	 + Increased ALP (marked) + Increased ALT (mild) + Increased cholesterol + Decreased Urea + Mildly increased glucose + Mild hypernatraemia and hypokalaemia 	+ Inadequate specific gravity (typically < 1.020)+ Proteinuria+ Bacteriuria

Predisposed breeds

- + Miniature poodle
- + Dachshund

+ Hypertension

- + Terrier breeds
- + Boxer
- + Standard schnauzer

Indications for testing

Test patients:

- + With multiple clinical signs of disease.
- + With multiple laboratory abnormalities consistent with Cushing's syndrome.
- + Without any other underlying disease (or with a controlled underlying disease).
- + Who have not received any corticosteroids (topical, oral, or injectable) as these affect testing.

Important: Testing patients who do not meet these criteria can lead to false-positive results.

How to confirm hypercortisolism

A dynamic test is required to diagnose hypercortisolism. There are two different dynamic testing options:

Low-dose dexamethasone suppression test (LDDST):

+ This is the test of choice in most cases because it can confirm the diagnosis and sometimes differentiate between pituitary and adrenal disease.¹⁻³

ACTH stimulation test (ACTHST):

- + May be less affected by the stress of an underlying condition, such as diabetes mellitus.3
- + 1-hour test protocol (ideal for high-paced practices).
- + Can be used to help monitor patients on therapy for Cushing's syndrome.
- + This is the only test that diagnoses iatrogenic Cushing's syndrome.


Note: LDDST and ACTHST can both be affected by the administration of exogenous steroids or by stress related to nonadrenal illness.

To run an LDDST:

- 1. Collect a baseline cortisol sample.
- Administer 0.01 mg/kg IV dexamethasone sodium phosphate or dexamethasone in polyethylene glycol.
- 3. 4 hours after injection, collect a second blood sample.*
- 4. 8 hours after injection, collect a third blood sample.


To run an ACTHST:

- 1. Collect a pre-ACTH sample.
- Administer synthetic ACTH IV (5 μg/kg or up to 250 μg per dog).
- 3. 1 hour after injection, collect a post-ACTH sample.







Diagnosing Cushing's syndrome.




General algorithm: Diagnosing Cushing's syndrome with LDDST.



Full algorithm: Diagnosing Cushing's syndrome with LDDST.



Diagnosing Cushing's syndrome using ACTHST.



Differentiating between pituitary vs. adrenal-dependent hypercortisolism using HDDST.


The ACTH stimulation test (ACTHST) cannot differentiate between pituitary-dependent hypercortisolism (PDH) and adrenal-dependent hypercortisolism (ADH), and in some cases, the low-dose dexamethasone suppression test (LDDST) may also be nondiscriminatory. If differentiation is unclear, additional testing is necessary in order to guide treatment and provide prognostic information. Abdominal ultrasound is typically the most practical next step, although endogenous ACTH concentration or a high-dose dexamethasone suppression test (HDDST) can also be informative. Studies indicate that approximately 12% of dogs with PDH fail to suppress on an LDDST, yet do demonstrate suppression on an HDDST.⁴

Importantly, the HDDST should not be used to diagnose hypercortisolism – this test should only be performed after the disease has been confirmed using LDDST or ACTHST.

To run an HDDST:

- 1. Collect a baseline cortisol sample.
- 2. Administer 0.1 mg/kg IV dexamethasone sodium phosphate or dexamethasone in polyethylene glycol.
- 3. 4 hours after injection, collect a second blood sample.
- 4. 8 hours after injection, collect a third blood sample.

Please note that administration of exogenous steroids or stress related to nonadrenal illness may affect the results and interpretation of the HDDST.



Monitoring dogs on trilostane therapy.

Trilostane therapy should be adjusted to the needs of the individual patient based on monitoring clinical signs, results of cortisol testing, and a biochemistry panel (including electrolytes).


After beginning trilostane therapy, patients should be monitored at 10–14 days, 30 days, 90 days, and then every 3 months. Also, patients should be monitored 10–14 days after any dose adjustment.⁵

There are several methods for monitoring cortisol in a patient on trilostane therapy.

- + ACTHST test performed 2-3 hours post-administration.
 - + When monitoring a patient over time, it is important to begin the ACTHST at the same time after trilostane administration each time the ACTHST is performed.
- + Pre-administration resting cortisol test performed immediately prior to administration of morning trilostane pill.

Results should be interpreted and treatment decisions made in light of the clinical signs. Exact drug manufacturer recommendations may vary by region.


Monitoring with ACTHST.



If using ACTH-depot (ACTH gel) for procedure, evaluate both the 1-hour and 2-hour post-ACTH cortisol – use the higher result to interpret the test

Monitoring with pre-administration resting cortisol.

Correlation with clinical signs and haematology and biochemistry results is essential for correct interpretation of pre-administration resting cortisol results.



Always interpret cortisol results in conjunction with clinical signs and owner feedback. If the dog is doing well clinically, even a slightly high or low cortisol result may not require immediate dose adjustment

Hypoadrenocorticism

Pathophysiology

Primary hypoadrenocorticism (HA)


This is most common form of the disease; it results from failure of the adrenal cortex to produce adequate glucocorticoids and mineralocorticoids. This typically occurs due to adrenal cortical atrophy secondary to immune-mediated destruction. Less commonly, primary HA may result from infiltrative or destructive processes affecting both adrenal glands, such as neoplasia, fungal infection, haemorrhage, or infarction. latrogenic primary HA can also occur following the administration of adrenal-targeting drugs such as mitotane or trilostane.^{1,6}


Eunatraemic, eukalaemic hypoadrenocorticism

Formerly referred to as atypical Addison's disease, this form is characterised by reduced glucocorticoid secretion with normal electrolyte levels. While some patients eventually develop electrolyte abnormalities consistent with typical Addison's disease, others maintain normal electrolyte levels throughout their lives.¹

Secondary hypoadrenocorticism

This is an uncommon form of hypoadrenocorticism resulting from insufficient ACTH secretion, leading to glucocorticoid deficiency, while mineralocorticoid production typically remains unaffected. In rare cases, mineralocorticoid deficiency may also occur due to impaired renin activity. Secondary hypoadrenocorticism may occur naturally, due to pituitary or hypothalamic dysfunction, or it may be iatrogenic due to surgery on the glands of the HPAA or abrupt withdrawal of glucocorticoid medication. ^{1,6}





Clinical signs

- + Can be vague
- + Mild to severe
- + May wax and wane
- + Anorexia, weight loss
- + Vomiting, diarrhoea
- + Lethargy, weakness, shaking, collapse
- + Polyuria/polydipsia

Note: Sometimes stressful situations can push a borderline compensated dog with HA into an adrenal crisis.

Predisposed breeds

- + Leonberger
- + Pomeranian
- + Great Dane
- + Standard poodle
- + Bearded collie
- + Portuguese water dog
- + Cocker spaniel
- + Springer spaniel

Clinicopathologic findings

Haematology

- + Lack of a stress leucogram (most consistent finding in a sick animal: normal to increased lymphocytes)
- + Mild anaemia

Chemistry

- + Hyponatraemia + Hyperkalaemia
- + Hypoglycaemia
- + Hypoalbuminaemia+ Hypocholesterolaemia
- + Hypercalcaemia
- + Elevated ALT/ALP
- + Azotaemia

Urinalysis


+ Inadequately concentrated urine in presence of dehydration

Screening for hypoadrenocorticism with resting cortisol

It is unlikely that a dog who has hypoadrencorticism will have a resting (baseline) cortisol concentration of $\geq 2.00~\mu g/dL$ (55.2 nmol/L). Therefore, resting cortisol is a very sensitive test for ruling out hypoadrenocorticism in dogs with clinical signs. However, resting cortisol is not a specific test for hypoadrenocorticism. Therefore, ACTHST is required to confirm the diagnosis. 6

Please note that a dog with hypoadrenocorticism that has been administered a glucocorticoid that cross-reacts with the assay (e.g., prednisone) may have results \geq 2.00 µg/dL (55.2 nmol/L). Therefore, it is important to establish a full medical history.

Diagnosing Addison's disease with ACTHST.





References

- 1. Project ALIVE. European Society of Veterinary Endocrinology. Accessed July 11, 2025. www.esve.org/alive/intro.aspx
- 2. Galac S. Hyperadrenocorticism (Cushing's syndrome) in dogs. In: Ettinger S.J., Feldman EC, Côté E, eds. Ettinger's Textbook of Veterinary Internal Medicine Expert Consult. Vol 2. 9th ed. Elsevier; 2024:2004–2021.
- 3. Bugbee A, Rucinsky R, Cazabon S, et al. 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines. J Am Anim Hosp Assoc. 2023;59(3):113-135. doi:10.5326/JAAHA-MS-7368
- 4. Behrend EN, Kooistra HS, Nelson R, Reusch CE, Scott-Moncrieff JC. Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM consensus statement (small animal). J Vet Intern Med. 2013;27(6):1292-1304. doi:10.1111/jvim.12192
- 5. Treating Cushing's. Dechra. Accessed July 11, 2025. www.dechra-us.com/management-areas/companion-animals/endocrinology/canine-hyperadrenocorticism/treating-cushings
- 6. Hess RS. Hypoadrenocorticism. In: Ettinger SJ, Feldman EC, Côté E, eds. Ettinger's Textbook of Veterinary Internal Medicine Expert Consult. Vol 2. 9th ed. Elsevier; 2024:2036–2045.

